Logo image of ACER

ACER THERAPEUTICS INC (ACER) Stock Fundamental Analysis

NASDAQ:ACER - Nasdaq - US00444P1084 - Common Stock - Currency: USD

0.9  +0.03 (+3.41%)

After market: 0.8005 -0.1 (-11.06%)

Fundamental Rating

0

ACER gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. ACER has a bad profitability rating. Also its financial health evaluation is rather negative. ACER has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ACER has reported negative net income.
ACER had a negative operating cash flow in the past year.
ACER had negative earnings in each of the past 5 years.
In the past 5 years ACER always reported negative operating cash flow.
ACER Yearly Net Income VS EBIT VS OCF VS FCFACER Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M

1.2 Ratios

ACER has a worse Return On Assets (-225.71%) than 92.72% of its industry peers.
Industry RankSector Rank
ROA -225.71%
ROE N/A
ROIC N/A
ROA(3y)-141.6%
ROA(5y)-120.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACER Yearly ROA, ROE, ROICACER Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 200 -200 400 -400 600 800

1.3 Margins

ACER does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACER Yearly Profit, Operating, Gross MarginsACER Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 -200 -400 -600 -800 -1K

More info and screens

0

2. Health

2.1 Basic Checks

ACER does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ACER has been increased compared to 1 year ago.
Compared to 1 year ago, ACER has a worse debt to assets ratio.
ACER Yearly Shares OutstandingACER Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M
ACER Yearly Total Debt VS Total AssetsACER Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -25.07, we must say that ACER is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -25.07, ACER is doing worse than 91.75% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -25.07
ROIC/WACCN/A
WACC9.13%
ACER Yearly LT Debt VS Equity VS FCFACER Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.19 indicates that ACER may have some problems paying its short term obligations.
ACER has a Current ratio of 0.19. This is amonst the worse of the industry: ACER underperforms 97.09% of its industry peers.
ACER has a Quick Ratio of 0.19. This is a bad value and indicates that ACER is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of ACER (0.19) is worse than 96.12% of its industry peers.
Industry RankSector Rank
Current Ratio 0.19
Quick Ratio 0.19
ACER Yearly Current Assets VS Current LiabilitesACER Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

ACER shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -88.64%.
Looking at the last year, ACER shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-88.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-74.19%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 35.01% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y55.45%
EPS Next 2Y44%
EPS Next 3Y35.01%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACER Yearly Revenue VS EstimatesACER Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2021 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M
ACER Yearly EPS VS EstimatesACER Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10 -20 -30 -40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ACER reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ACER is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACER Price Earnings VS Forward Price EarningsACER Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACER Per share dataACER EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as ACER's earnings are expected to grow with 35.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44%
EPS Next 3Y35.01%

More info and screens

0

5. Dividend

5.1 Amount

ACER does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACER THERAPEUTICS INC

NASDAQ:ACER (11/8/2023, 8:19:05 PM)

After market: 0.8005 -0.1 (-11.06%)

0.9

+0.03 (+3.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-15 2023-11-15/amc
Earnings (Next)03-25 2024-03-25/amc
Inst Owners1.19%
Inst Owner Change0%
Ins Owners0.02%
Ins Owner Change0%
Market Cap22.01M
Analysts80
Price Target1.53 (70%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.22%
Min EPS beat(2)-43.08%
Max EPS beat(2)55.52%
EPS beat(4)2
Avg EPS beat(4)8%
Min EPS beat(4)-51.19%
Max EPS beat(4)70.76%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-86.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-16.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.66
EYN/A
EPS(NY)-0.74
Fwd EYN/A
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.24
OCFYN/A
SpS0
BVpS-0.69
TBVpS-1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -225.71%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-141.6%
ROA(5y)-120.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score0
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 259.19%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.19
Quick Ratio 0.19
Altman-Z -25.07
F-Score0
WACC9.13%
ROIC/WACCN/A
Cap/Depr(3y)116.99%
Cap/Depr(5y)196.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-88.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-74.19%
EPS Next Y55.45%
EPS Next 2Y44%
EPS Next 3Y35.01%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-91.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15924.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22323.8%
OCF growth 3YN/A
OCF growth 5YN/A